Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)

Clinical trial NCT05329649 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05329649
Sponsor: Vertex Pharmaceuticals Incorporated
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Sickle Cell Disease Hydroxyurea Failure Hydroxyurea Intolerance Hemoglobinopathies Hematological Diseases

Start date: 2022-05-02
Primary completion: 2027-06-06
Enrollment: 13

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.